Figure 4 | Scientific Reports

Figure 4

From: The Beta-adrenergic agonist, Ractopamine, increases skeletal muscle expression of Asparagine Synthetase as part of an integrated stress response gene program

Figure 4

Expression of ATF4 is not altered by BA treatment but Atf5 mRNA is increased. (A) mRNA abundance of activating transcription factor 4. (B) Validation of anti-ATF4 antibody to detect ATF4 from protein extracted from cultured porcine muscle cells treated with or without thapsigargin (TG) - see supplementary figure 2 for full blot and gel. (C) Representative western blots attempting to detect ATF4 protein in muscle samples from BA, control or GH treated pigs (see supplementary Figure 3 for full blots). (D) qPCR validation of activating transcription factor 5 gene expression. (E) CCAAT/enhancer binding protein gamma mRNA abundance measured by qPCR. ^indicates a treatment effect with p < 0.01, &indicates a treatment effect with p < 0.05, aindicates a significant Dunnetts test with p < 0.05 for BA vs. control (GH vs. control = NS), bindicates a significant Dunnetts test with p < 0.01 for BA vs. control (GH vs. control = NS). Data is mean ± SEM. Days 1, 3, 7 and 13 have n = 10 whilst day 27 has n = 15. White bars = control, black bars = GH (growth hormone), grey bars = BA (beta-adrenergic agonist).

Back to article page